PubRank

Mark Connor

Author PubWeight™ 26.07‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Opioids: cellular mechanisms of tolerance and physical dependence. Curr Opin Pharmacol 2005 1.82
2 Opioid agonists have different efficacy profiles for G protein activation, rapid desensitization, and endocytosis of mu-opioid receptors. J Biol Chem 2003 1.78
3 Capsaicin activation of glutamatergic synaptic transmission in the rat locus coeruleus in vitro. J Physiol 2002 1.29
4 Opioid tolerance in periaqueductal gray neurons isolated from mice chronically treated with morphine. Br J Pharmacol 2005 1.16
5 Gingerols: a novel class of vanilloid receptor (VR1) agonists. Br J Pharmacol 2002 1.11
6 Anandamide is a partial agonist at native vanilloid receptors in acutely isolated mouse trigeminal sensory neurons. Br J Pharmacol 2002 1.11
7 The role of opioid receptor phosphorylation and trafficking in adaptations to persistent opioid treatment. Neurosignals 2005 1.01
8 Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine. Br J Pharmacol 2009 1.01
9 Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol. J Biol Chem 2008 1.00
10 Real-time characterization of cannabinoid receptor 1 (CB1 ) allosteric modulators reveals novel mechanism of action. Br J Pharmacol 2013 0.97
11 Prostaglandin E(2) inhibits calcium current in two sub-populations of acutely isolated mouse trigeminal sensory neurons. J Physiol 2002 0.96
12 A continuous, fluorescence-based assay of μ-opioid receptor activation in AtT-20 cells. J Biomol Screen 2012 0.89
13 TRPV1 antagonists as a potential treatment for hyperalgesia. Recent Pat CNS Drug Discov 2006 0.87
14 Sumatriptan inhibits synaptic transmission in the rat midbrain periaqueductal grey. Mol Pain 2008 0.86
15 The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse. ACS Chem Neurosci 2013 0.84
16 Decreased mu-opioid receptor signalling and a reduction in calcium current density in sensory neurons from chronically morphine-treated mice. Br J Pharmacol 2006 0.84
17 Lack of functional expression of NMDA receptors in PC12 cells. Neurotoxicology 2007 0.81
18 Pharmacological characterization of a recombinant, fluorescent somatostatin receptor agonist. Bioconjug Chem 2011 0.81
19 Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human μ-opioid receptor (OPRM1). Br J Pharmacol 2014 0.81
20 Methanandamide activation of a novel current in mouse trigeminal ganglion sensory neurons in vitro. Neuropharmacology 2007 0.81
21 A real-time, fluorescence-based assay for measuring μ-opioid receptor modulation of adenylyl cyclase activity in Chinese hamster ovary cells. J Biomol Screen 2013 0.80
22 Inhibition of human recombinant T-type calcium channels by N-arachidonoyl 5-HT. Br J Pharmacol 2012 0.79
23 Buprenorphine signalling is compromised at the N40D polymorphism of the human μ opioid receptor in vitro. Br J Pharmacol 2014 0.78
24 The results of an experimental indoor hydroponic Cannabis growing study, using the 'Screen of Green' (ScrOG) method-Yield, tetrahydrocannabinol (THC) and DNA analysis. Forensic Sci Int 2010 0.78
25 Targeting somatostatin receptors using in situ-bioconjugated fluorescent nanoparticles. Nanomedicine (Lond) 2012 0.77
26 Convulsant actions of calycanthine. Toxicol Appl Pharmacol 2003 0.77
27 A6V polymorphism of the human μ-opioid receptor decreases signalling of morphine and endogenous opioids in vitro. Br J Pharmacol 2015 0.75
28 Development of Bright and Biocompatible Nanoruby and its Application to Background-free Time-gated Imaging of G-protein Coupled Receptors. ACS Appl Mater Interfaces 2017 0.75
29 Fluorescence-based, high-throughput assays for μ-opioid receptor activation using a membrane potential-sensitive dye. Methods Mol Biol 2015 0.75